Markets 1 sources

Tempus AI (TEM) Projected to Win $600 Million Cancer Vaccine Sequencing Revenue

Covered by 1 source · 1 article

BTIG projects Tempus AI could earn over $600 million sequencing revenue if the Moderna-Merck cancer vaccine is approved, with MRD testing a longer-term prize.

Covered by

Coinotag

All coverage

Tempus AI (TEM) Projected to Win $600 Million Cancer Vaccine Sequencing Revenue

CoinOtag 1h ago

Tempus AI (TEM) Projected to Win $600 Million Cancer Vaccine Sequencing Revenue

BTIG projects Tempus AI could earn over $600 million sequencing revenue if the Moderna-Merck cancer vaccine is approved, with MRD testing a longer-term prize.